Myxoid Liposarcoma (MLPS) is an uncommon and highly destructive subtype of soft tissue sarcoma, typically diagnosed in people in their 40s and 50s. Protheragen provides all MLPS R & D-related services, including but not limited to diagnostics, therapeutics development, preclinical research, and tailored options.
Overview of Myxoid Liposarcoma (MLPS)
Myxoid Liposarcoma (MLPS) is a rare form of soft tissue sarcoma that is distinguished by particular clinical behaviors and differences in its genetics. It forms the second most common subtype of liposarcoma, constituting 30% of all liposarcomas and 10% of all soft tissue sarcomas. MLPS is mostly seen in the deep soft tissues of the thighs, with its onset typically in middle age. The disease has a hallmark chromosomal translocation, most often t (12;16) (q13; p11), which fuses the FUS gene to a DDIT3 (CHOP) gene. This translocation is associated with the production of an oncogenic fusion protein, which contributes to the disease.
Fig.1 Representative photomicrographs of H & E stain (A) and DDIT3 immunohistochemistry (B) in a high-grade myxoid/round cell liposarcoma with diffuse and strong DDIT3 expression. (Scapa J. V.,
et al., 2021)
Diagnostics Development for Myxoid Liposarcoma (MLPS)
Histopathological Examination
Histopathological examination is a cornerstone in the diagnosis of MLPS. The tumor is characterized by a myxoid stroma with spindle-shaped cells, lipoblasts, and a network of arborizing capillaries. High-grade variants may show hypercellular areas with round cells. This detailed histological analysis helps differentiate MLPS from other soft tissue sarcomas and benign lipomatous tumors.
Immunohistochemistry
Immunohistochemistry plays a crucial role in the diagnosis of MLPS. The use of specific antibodies, such as those targeting DDIT3, can help identify the presence of the characteristic fusion protein. Diffuse nuclear expression of DDIT3 is a hallmark of MLPS and can be detected using immunohistochemical staining. This method provides a rapid and relatively inexpensive means of diagnostic confirmation that is more broadly accessible to surgical pathology laboratories.
Molecular Testing
Molecular testing, including reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH), is used to detect the characteristic FUS-DDIT3 or EWSR1-DDIT3 fusion genes. These techniques offer high sensitivity and specificity for identifying the genetic alterations associated with MLPS, confirming the diagnosis and guiding targeted therapy.
Radiological Imaging
Radiological imaging, such as MRI and CT scans, is essential for assessing the size, location, and extent of the tumor. These imaging modalities help in staging the disease, detecting metastases, and planning surgical resection. Advanced imaging techniques can also provide valuable information on tumor vascularity and potential response to therapy.
Therapeutics Development for Myxoid Liposarcoma (MLPS)
- Chemotherapy
Chemotherapy remains one of the cornerstone therapeutics for MLPS, particularly in cases where surgical resection is not feasible or in metastatic disease. The most commonly used agents include doxorubicin and ifosfamide, both of which have shown efficacy in reducing tumor size and preventing recurrence in high-grade and metastatic MLPS. Doxorubicin, an anthracycline, interferes with DNA replication, while ifosfamide, an alkylating agent, cross-links DNA strands, preventing tumor cell proliferation.
- Targeted Therapy and Emerging Agents
Given the molecular basis of MLPS, targeted therapies are being explored to address the underlying genetic abnormalities. Trabectedin, an alkaloid derived from marine organisms, has shown promising results in MLPS by inducing DNA damage and cell death in tumor cells, particularly in tumors with FUS-DDIT3 translocations. Additionally, agents targeting angiogenesis, such as axitinib, are being evaluated for their potential to inhibit tumor vascularization, thus preventing metastasis and tumor progression.
Table 1. Therapeutics of Myxoid Liposarcoma (MLPS).
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Doxorubicin |
DNA intercalation |
Used as adjuvant therapy in high-grade or metastatic MLPS. It inhibits DNA synthesis, leading to cell death. |
Approved |
| Chemotherapy |
Ifosfamide |
Alkylating agent |
Used in combination with doxorubicin for high-risk primary MLPS. It cross-links DNA, disrupting cell division. |
Approved |
| Hyperthermia |
N/A |
Thermal enhancement |
Used in combination with radiotherapy to enhance the effectiveness of therapy by increasing tumor temperature. |
Approved |
| Chemotherapy |
Trabectedin |
DNA minor groove binder |
Demonstrated significant efficacy in advanced localized MLPS. It binds to DNA, causing cell cycle arrest and apoptosis. |
Phase II |
| Targeted Therapy |
Axitinib |
Tyrosine kinase inhibitor |
Targets the VEGF signaling pathway, exerting anti-angiogenic and anti-tumorigenic effects. |
Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers a range of customized services for MLPS research and therapeutic development. Our diagnostic services encompass a broad range of imaging, histopathology, and molecular technologies to ensure the accurate development of MLPS diagnostics. Our therapeutic drug development services focus on the discovery and optimization of new drugs and therapies, utilizing cutting-edge technologies and a multidisciplinary approach to meet the diverse needs of our clients.
Disease Models
- MLS 2645-95, MLS 1765-92, and MLS 402-91 Cell Lines
- Ef1a-Driven FUS-CHOP Models
- Akt2-Driven Zebrafish Models
- Patient-Derived Xenograft Models
Protheragen's diagnostics and therapeutics development services are characterized by their scientific rigor, innovation, and attention to detail. We employ a multidisciplinary team of experts, including oncologists, pathologists, molecular biologists, and pharmacologists, to ensure a comprehensive and integrated approach to MLPS research. If you are interested in our services, please feel free to contact us.
References
- Scapa, Jason V., et al. "DDIT3 immunohistochemistry is a useful tool for the diagnosis of myxoid liposarcoma." The American journal of surgical pathology 45.2 (2021): 230-239.
- Potkrajcic, Vlatko, et al. "Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis." Strahlentherapie und Onkologie (2025): 1-10.
- Tfayli, Yehia, et al. "Management of myxoid liposarcoma of the extremity." Oncology Letters 22.2 (2021): 596.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
